Evidence map›Paper›PMID 38994444›Full record

ArticleOpen forum infectious diseases2024

Hospital Burden of All-Cause Pneumonia and Nonbacteremic Pneumococcal Pneumonia in Adults in France Between 2013 and 2019.

Ayman Sabra, Marie Bourgeois, Emmanuelle Blanc, Stephane Fievez, Jennifer Moïsi, Gwenaël Goussiaume, Magali Lemaitre, Laurence Watier, Nicolas Coulombel, Julien Tréhony and 3 more

Abstract read
In one paragraph

Article in Open forum infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ayman SabraMedical Affairs, Vaccines, Antivirals and Evidence Generation, Pfizer, Paris, France.ORCID https://orcid.org/0000-0001-7971-4652
Marie BourgeoisVaccines Department, Pfizer, Paris, France.
Emmanuelle BlancVaccines Department, Pfizer, Paris, France.
Stephane FievezHealth and Value Department, Pfizer, Paris, France.
Jennifer MoïsiMedical Affairs, Vaccines, Antivirals and Evidence Generation, Pfizer, Paris, France.
Gwenaël GoussiaumeVaccines Department, Pfizer, Paris, France.
Magali LemaitreReal World Solutions, IQVIA, Courbevoie, France.
Laurence WatierEpidemiology and modelling of antibacterial evasion, Institut Pasteur, Paris, France.
Nicolas CoulombelReal World Solutions, IQVIA, Courbevoie, France.
Julien TréhonyReal World Solutions, IQVIA, Courbevoie, France.
Aurore TricotelReal World Solutions, IQVIA, Courbevoie, France.
Yasmine BaghdadiReal World Solutions, IQVIA, Courbevoie, France.
Muriel S FartoukhAssistance Publique-Hôpitaux de Paris, Sorbonne Université, Service de médecine intensive réanimation, Hôpital Tenon, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Community-acquired pneumonia (CAP) is associated with significant morbidity and mortality. The study objective was to describe the hospital burden of pneumonia in the adult population in France. Methods: This retrospective study was conducted from the National Health Insurance Database. All hospitalizations for pneumonia (all-cause) between 2013 and 2019 were included. Different risk categories for patients were established based on pneumococcal vaccine recommendations by French health authorities. Results: A total of 2 199 240 episodes of CAP were registered over the study period (annual mean, 314 177 [standard deviation, 17 818.6]); 75% occurred in patients aged ≥65 years, among whom 47% were not classified in the moderate- or high-risk categories recommended for French pneumococcal vaccination. The incidence of CAP increased with age (117.9, 395.3, and 1916.7 per 100 000 for the age groups 18-49, 50-64, and ≥65 years, respectively, in 2019). Furthermore, being at risk of pneumococcal disease resulted in more severe outcomes, including longer episode duration (mean, 14 days in low-risk vs 17 days in high-risk patients) and higher risk of referral to critical care units (from 20% to 27%), of rehospitalization up to 180 days (from 39% to 67%), of in-hospital death (from 12% to 19%), and of 1-year mortality (from 26% to 49%). Conclusions: This study establishes the incidence of CAP in adults in France, describes the significant burden of disease, and highlights the need for better prevention policies.

Indexed as

Francemortalitypneumococcal diseasepneumoniaStreptococcus pneumoniae vaccination

Identifiers

PMID38994444
PMCPMC11237635

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.